Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × Bevacizumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Colorectal Neoplasms 382 Carcinoma, Non-Small-Cell Lung 196 Breast Neoplasms 166 Ovarian Neoplasms 148 Glioblastoma 134 Neoplasms 110 Carcinoma, Hepatocellular 101 Rectal Neoplasms 97 Colonic Neoplasms 95 Neoplasm Metastasis 91 Brain Neoplasms 85 Lung Neoplasms 74 Fallopian Tube Neoplasms 69 Glioma 62 Carcinoma, Renal Cell 61 Pancreatic Neoplasms 45 Melanoma 39 Gliosarcoma 39 Adenocarcinoma of Lung 36 Liver Neoplasms 35 Stomach Neoplasms 34 Uterine Cervical Neoplasms 33 Recurrence 33 Astrocytoma 28 Triple Negative Breast Neoplasms 24 Endometrial Neoplasms 24 Carcinoma, Ovarian Epithelial 23 Esophageal Neoplasms 21 Kidney Neoplasms 19 Colorectal Cancer Metastatic 18

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡